Effect of osteoporosis therapy with RANKL inhibitor on coronary calcifications
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2019
Price : $35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- 11 Mar 2019 Status changed from active, no longer recruiting to completed.
- 19 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Apr 2017 New trial record